Recorded device evidence

DIAMONDBACK 360 PERIPHERAL ORBITAL ATHERECTOMY SYSTEM (K133999): indications, design and recorded evidence

The acquired K133999 file contains product-specific indications and users, design and operating principle, performance evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-08. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 22 selected decisions under primary code MCW. 22 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

Calendar elapsed days: lower quartile 46.2, median 83.0, upper quartile 139.0. These are recorded calendar differences, not active FDA review time.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K133999 ↗ · this pageDIAMONDBACK 360 PERIPHERAL ORBITAL ATHERECTOMY SYSTEM2013-12-27 → 2014-02-2863Special
K260244 ↗Auryon Atherectomy System2026-01-27 → 2026-04-1073Traditional
K250723 ↗FreedomFlow™ Orbital Circumferential Atherectomy System (H6005/ 4Fr 3-Sphere Configuration)2025-03-10 → 2025-04-2546Special
K250385 ↗Turbo-Elite Laser Atherectomy Catheter2025-02-11 → 2025-03-1330Special
K242757 ↗Rotarex Atherectomy System2024-09-12 → 2025-01-30140Special

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K133999 · PDF page 2 ↗ Source 2

The         Diamondback          360        Peripheral             Orbital         Atherectomy              System          is a percutaneous            orbital
                   atherectomy               system       indicated        for         use      as     therapy           in patients          with        occlusive       atherosclerotic
                   disease        in  peripheral             arteries        and      who         are         acceptable        candidates          for      percutaneous
                   transluminal        atherectomy.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K133999 · PDF page 1 ↗ Source 3

The       Diamondback          360       Peripheral         Orbital         Atherectomy            System        (OAS)              is         intended       for      use
                                       in    the    treatment         of peripheral       arteries           and      A-V         graft       (shunt)         stenosis.
                                       The       OAS           provides         a method         of removing           stenotic      material              from     peripheral             arteries        and
                                      A-V        grafts.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Performance evidence actually described

K133999 · PDF page 2 ↗ Source 2

The        Diamondback          360        Peripheral             Orbital        Atherectomy          System        was        evaluated       using      the
                    following      performance              bench    testing          to      confirm       the        performance            characteristics             as
                   compared          to     the          predicate         device.

Compare with your product: The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK133999 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryDIAMONDBACK 360 PERIPHERAL ORBITAL ATHERECTOMY SYSTEM [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantCardiovascular Systems, Inc. [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeMCW [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2014-02-28 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeSpecial [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2013-12-27 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Performance evidence actually described — what differs in our product?

    The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

    Useful evidence: The cited narrative and full tables, underlying protocols/results and a reviewed comparison with the proposed product.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[140633] · record d0aeb4a14d35469a533743bd0ba9f4ea2548c741c48488ad2cde8a7fd8d88890
  • [4] Complete results array / fda-decision-context:K133999 · record whole dataset partition

FDA 510(k) summary — K133999 ↗

Tue, 25 Mar 2014 12:27:37 GMT · retrieved 2026-10-08

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot 39ad36ed60a70c78cc8c05c229ad107f68d25c4cf0bf274af3a384b8457c0c36

  • [2] PDF page 2 · record 8c674927809dce22d663e3cd57276ec07e1451c29ead846886da74f11fc42a37
  • [3] PDF page 1 · record 6c534c570b8aecb245cfbbd004a8b75b8f89c33e3b9854e09e89dffb04ff3108

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services